Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago
Overview
Authors
Affiliations
Background: Identifying factors associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs) may help health systems optimize SARS-CoV-2 infection control strategies.
Methods: We conducted a cross-sectional analysis of baseline data from the Northwestern HCW SARS-CoV-2 Serology Cohort Study. We used the Abbott Architect Nucleocapsid IgG assay to determine seropositivity. Logistic regression models (adjusted for demographics and self-reported community exposure to coronavirus disease 2019 [COVID-19]) were fit to quantify the associations between occupation group, health care delivery tasks, and community exposure and seropositive status.
Results: A total of 6510 HCWs, including 1794 nurses and 904 non-patient-facing administrators, participated. The majority were women (79.6%), 74.9% were White, 9.7% were Asian, 7.3% were Hispanic, and 3.1% were non-Hispanic Black. The crude prevalence of seropositivity was 4.8% (95% CI, 4.6%-5.2%). Seropositivity varied by race/ethnicity as well as age, ranging from 4.2% to 9.6%. Out-of-hospital exposure to COVID-19 occurred in 9.3% of HCWs, 15.0% (95% CI, 12.2%-18.1%) of whom were seropositive; those with family members diagnosed with COVID-19 had a seropositivity rate of 54% (95% CI, 44.2%-65.2%). Support service workers (10.4%; 95% CI, 4.6%-19.4%), medical assistants (10.1%; 95% CI, 5.5%-16.6%), and nurses (7.6%; 95% CI, 6.4%-9.0%) had significantly higher seropositivity rates than administrators (referent; 3.3%; 95% CI, 2.3%-4.4%). However, after adjustment, nursing was the only occupation group with a significantly higher odds (odds ratio, 1.9; 95% CI, 1.3-2.9) of seropositivity. Exposure to patients receiving high-flow oxygen therapy and hemodialysis was significantly associated with 45% and 57% higher odds for seropositive status, respectively.
Conclusions: HCWs are at risk for SARS-CoV-2 infection from longer-duration exposures to people infected with SARS-CoV-2 within health care settings and their communities of residence.
Bansal A, Trieu M, Eriksson E, Zhou F, McVernon J, Brokstad K Sci Rep. 2025; 15(1):4705.
PMID: 39922967 PMC: 11807171. DOI: 10.1038/s41598-025-89472-5.
Des Soye B, McGee J, Hollas M, Forte E, Fellers R, Melani R Anal Chem. 2024; .
PMID: 39143757 PMC: 11825902. DOI: 10.1021/acs.analchem.4c01962.
Moskowitz J, Jackson K, Cummings P, Addington E, Freedman M, Bannon J PLoS One. 2024; 19(6):e0305172.
PMID: 38913665 PMC: 11195972. DOI: 10.1371/journal.pone.0305172.
Niekrens V, Kunz B, Werner M, Valenza G, Seggewies C, Bogdan C Heliyon. 2024; 10(9):e30311.
PMID: 38726181 PMC: 11079082. DOI: 10.1016/j.heliyon.2024.e30311.
Valdivia N, Hirschhorn L, Vu T, Dubois C, Moskowitz J, Wilkins J Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e58.
PMID: 38698942 PMC: 11062791. DOI: 10.1017/ash.2024.17.